Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of "Buy" from Analysts

Key Points

• Analyst sentiment is broadly positive: Twenty firms give Definium Therapeutics an average “Buy” rating, with 17 buys, two strong buys and one sell. The average 12-month price target is $63, though recent targets range from $55 to $90.
• The stock has pulled back while remaining volatile: DFTX opened at $38.50, down 3.1%, with a 52-week range of $8.70 to $49.70 and a beta of 2.23. The company reported a quarterly loss of $1.44 per share, substantially worse than the expected $0.55 loss.
• Insiders have been net sellers: Company insiders sold 48,096 shares worth about $2.17 million over the past 90 days, while insiders retain a 2.40% ownership stake. Institutional investors own 27.91% of the company.

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) have received an average rating of "Buy" from the twenty ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seventeen have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $63.00.

DFTX has been the topic of several recent analyst reports. JonesTrading boosted their price objective on shares of Definium Therapeutics from $74.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, August 13th. Maxim Group set a $55.00 price target on Definium Therapeutics and gave the stock a "buy" rating in a research report on Friday, August 14th. Citigroup restated a "buy" rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Needham & Company LLC lifted their target price on Definium Therapeutics from $50.00 to $66.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Definium Therapeutics in a research note on Friday, July 17th.

Definium Therapeutics Stock Down 3.1%

NASDAQ:DFTX opened at $38.50 on Wednesday. Definium Therapeutics has a twelve month low of $8.70 and a twelve month high of $49.70. The firm has a market capitalization of $5.17 billion, a price-to-earnings ratio of -11.22 and a beta of 2.23. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock's 50 day moving average price is $44.03 and its two-hundred day moving average price is $29.11.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Equities research analysts expect that Definium Therapeutics will post -3.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of the firm's stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the sale, the insider owned 320,571 shares of the company's stock, valued at $14,435,312.13. This trade represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares of the company's stock, valued at approximately $9,433,199.61. This trade represents a 1.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 48,096 shares of company stock worth $2,165,763. Company insiders own 2.40% of the company's stock.

Institutional Trading of Definium Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nykredit A S bought a new position in Definium Therapeutics in the 2nd quarter valued at about $45,000. Russell Investments Group Ltd. boosted its holdings in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock worth $25,000 after acquiring an additional 2,003 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock worth $55,000 after acquiring an additional 3,020 shares during the period. Caxton Associates LLP acquired a new position in shares of Definium Therapeutics in the third quarter valued at approximately $126,000. Finally, AXQ Capital LP acquired a new position in shares of Definium Therapeutics in the second quarter valued at approximately $585,000. Institutional investors own 27.91% of the company's stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source